Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695250 · ClinicalTrials.gov registry record · Phase 1
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
A Phase 1 study, sponsored by Edward Kim.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03695250 is a Phase 1 study that was terminated before completion, run by Edward Kim. The registered enrollment target is 8 participants.
The verdict
NCT03695250, a Phase 1 study, was terminated before completion, sponsored by Edward Kim.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205 (BMS-986205) when given together with nivolumab and how well it works as first or second line therapy in treating patients with liver cancer. BMS-986205 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving BMS-986205 and nivolumab may work better in treating patients with liver cancer.
Interventions
- BIOLOGICAL Nivolumab
- DRUG IDO1 Inhibitor BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-10-16 |
| Est. Completion | 2021-03-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03695250
The ClinicalTrials.gov registry entry for NCT03695250 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edward Kim, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03695250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03695250 about?
NCT03695250 is a clinical study titled "BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer". This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205 (BMS-986205) when given together with nivolumab and how well it works as first or second line therapy in treating patients with liver cancer. BMS-986205 may stop the growth of tumor cells by blocking some of th...
What is the current status of trial NCT03695250?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-10-16. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT03695250?
The interventions under investigation include: Nivolumab (BIOLOGICAL), IDO1 Inhibitor BMS-986205 (DRUG).
Who is sponsoring clinical trial NCT03695250?
This trial is sponsored by Edward Kim, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.